Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system Thanks

Login for users with Unibas email account...

Login for registered users without Unibas email account...

Ethical issues of cutting edge biotechnology: Embedded interdisciplinary risk benefit evaluation of first-in-human trials in synthetic biology and nanomedicine
Third-party funded project
Project title Ethical issues of cutting edge biotechnology: Embedded interdisciplinary risk benefit evaluation of first-in-human trials in synthetic biology and nanomedicine
Principal Investigator(s) Elger, Bernice Simone
Co-Investigator(s) Hunziker, Patrick R.
Fussenegger, Martin
Biller-Andorno, Nikola
Project Members Satalkar, Priya
Shaw, David
Nast, Rebecca
Genske, Anna
Organisation / Research unit Ethik / Bio- und Medizinethik (Elger)
Project Website
Project start 01.08.2012
Probable end 29.02.2016
Status Completed

Embedded research related to existing or planned projects is urgently needed in synthetic biology and the field of nanomedicine. During the past 5 years, several US and European bodies have issued separate guidelines on the ethical issues of (a) synthetic biology and (b) nanotechnology and/or nanomedicine. These recommendations remain rather general and of limited help to researchers in these fields. Indeed, although many guidelines acknowledge the heterogeneity of research projects in the fields of both synthetic biology and nanotechnology and the need for individual ethical assessment of different research projects, they tend to address ethical issues in global terms. Most of these reports do not provide specific guidance to stakeholders who have to decide whether and under which circumstances a first-in-human trial is justified using any of the two new and promising technologies. Decision making concerns patients, scientists, policy makers and the public because of the various risks and benefits of these technologies. Possible risks are relevant not only for patients, factory worker and scientists in contact with the new devices and materials, but also for the wider population and the environment. In light of the considerable range and the complexity of the ethical questions, an interdisciplinary evaluation of present and future research projects is required bringing together the expertise of ethicists and scientists while taking into account patient values.

(a) Obtain data from the literature and the analysis of guidelines to compare decisions and criteria related to first-in-human trials using nanomedical or synthetic biology devices. Identify consensus and disagreement of guidelines and develop a synopsis about accepted and not accepted trials where the cut-off points become visible.
(b) Obtain comprehensive facts on benefits and harms as well as data on how experts and patients balance the conflicting values and what are their perceived needs for information and safeguards.
(c) Develop transparent strategies how to balance benefits and harms in 4 projects in Basel and in general. Propose evaluation steps that are helpful for researchers who plan FIH studies, funding sources and REC members who evaluate them, patients who make decisions to participate or not in these trials, as well as policy makers and society.

Both subprojects will evolve in parallel and contain 3 parts. The 1st part (a.) consists of a literature review of guidelines, of FIH trials in the two domains, and of studies on patient attitudes and informed consent. In the 2nd part (b.) data about knowledge and attitudes of 40 experts, 20 gout patients (i.), 100 other patients and 200 other possible participants of FIH trials (ii.) will be obtained through semi-structured interviews (i.) and a questionnaire study (ii.) using established social science methods of quantitative and qualitative research. The 3rd part (c.) uses classical methods of ethical analysis of FIH trials in general and of four specific projects in particular, and integrates stakeholders’ views examined in the previous parts.

The present study fills an important gap and is unique in that it combines, within one research module, the ethical evaluation of existing and planned cutting edge biotechnology studies in two departments and fields. The objective is to profit from the synergic effects of carrying out simultaneously the ethical evaluation of human trials concerning both D-BSSE research projects and future studies using nanomedicine devices. This is advantageous, first, because the so called converging technologies have some aspects in common when it comes to first-in-human trials. Second, the interaction and linkage of the two projects within the planned research module will be crucial to ensure comprehensive data collection on these important ethical issues and to realise a truly interdisciplinary endeavour necessary to find realistic and ethically acceptable solutions to the existing problems.
The project will permit to collect important new data and to cross-link results from the ethical analysis of FIH in both subprojects. It presents a unique opportunity to disseminate solutions and recommendations that have been developed in an interdisciplinary context, taking into account expert knowledge and opinions of different stakeholders.

Financed by Swiss National Science Foundation (SNSF)

Published results ()

  ID Autor(en) Titel ISSN / ISBN Erschienen in Art der Publikation
1462940  Genske, Anna; Engel, Sabrina; Elger, Bernice  Synthetische Prothese gegen Gicht? : ein möglicher Beitrag der hausärztlichen Praxis zur ethischen Beurteilung von klinischen Versuchen  1424-3776  Primary care  Publication: JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift) 
3289185  Genske, Anna; Engel-Glatter, Sabrina  Rethinking risk assessment for emerging technology first-in-human trials  1386-7423  Medicine, health care and philosophy  Publication: JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift) 
3373085  Satalkar, Priya; Shaw, David  Not fit for purpose: the ethical guidelines of the Indian Council of Medical Research  1471-8731  Developing world bioethics  Publication: JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift) 
3669405  Satalkar, Priya; Elger, Bernice Simone; Shaw, David  Naming it 'nano': Expert views on 'nano' terminology in informed consent forms of first-in-human nanomedicine trials  1743-5889 ; 1748-6963  Nanomedicine  Publication: JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift) 
3699854  Satalkar, Priya; Elger, Bernice Simone; Shaw, David.  Stakeholder views on participant selection for first-in-human trials in cancer nanomedicine  1198-0052  Current Oncology  Publication: JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift) 

Cooperations ()

  ID Kreditinhaber Kooperationspartner Institution Laufzeit - von Laufzeit - bis
1548683  Engel Glatter, Sabrina  Bedau, Mark Prof.  Reed College  01.08.2012  01.08.2015 
1548685  Engel Glatter, Sabrina  Andorno, Roberto  University Zurich  01.08.2012  01.08.2015 
2288769  Elger, Bernice Simone  Blume, Stuart, Prof. (second supervisor)  University of Amsterdam  01.08.2012  01.08.2015 

MCSS v5.8 PRO. 0.452 sec, queries - 0.000 sec ©Universität Basel  |  Impressum   |